Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets

Molecular and Cellular Endocrinology

Volumn 286, Issue 1-2 SUPPL. 1, 2008, Pages

  Matias, Isabel ^a,c   Petrosino, Stefania ^a   Racioppi, Alessandro ^a   Capasso, Raffaele ^b   Izzo, Angelo A ^b   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c INSTITUT FRANÇOIS MAGENDIE   (France)

Author keywords

2 Arachidonoylglycerol; Anandamide; Cannabinoid receptors; Vanilloid receptors

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ADRENALIN; ANANDAMIDE; ENDOCANNABINOID;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; ENDOCRINE FUNCTION; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LIPID COMPOSITION; LIPID DIET; LIPOLYSIS; MALE; METABOLIC REGULATION; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SKELETAL MUSCLE; THYROID GLAND; WHITE ADIPOSE TISSUE;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIETARY FATS; ENDOCANNABINOIDS; ENERGY METABOLISM; FASTING; HYPERGLYCEMIA; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; OBESITY; ORGAN SIZE; ORGAN SPECIFICITY;

EID: 42249099620     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.01.026     Document Type: Article

References (84)

1. Barna I., Zelena D., Arszovszki A.C., and Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci. 75 (2004) 2959-2970
2. Bátkai S., Mukhopadhyay P., Harvey-White J., Kechrid R., Pacher P., and Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H1689-H1695
3. Bensaid M., Gary-Bobo M., Esclangon A., Maffrand J.P., Le Fur G., Oury-Donat F., and Soubrie P. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 6 (2003) 908-914
4. Berger A., Crozier G., Bisogno T., Cavaliere P., Innis S., and Di Marzo V. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6402-6406
5. Bermúdez-Silva F.J., Suárez J., Baixeras E., Cobo N., Bautista D., Cuesta-Muñoz A.L., Fuentes E., Juan-Pico P., Castro M.J., Milman G., Mechoulam R., Nadal A., and Rodríguez de Fonseca F. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 51 (2008) 476-487
6. Bisogno T., Howell F., Williams G., Minassi A., Cascio M.G., Ligresti A., Matias I., Schiano-Moriello A., Paul P., Williams E.J., Gangadharan U., Hobbs C., Di Marzo V., and Doherty P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 163 (2003) 463-468
7. Bisogno T., Sepe N., Melck D., Maurelli S., De Petrocellis L., and Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322 (1997) 671-677
8. Bluher M., Engeli S., Klotinh N., Berndt J., Fasshauer M., Bátkai S., Pacher P., Schon M.R., Jordan J., and Stumvoll M. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55 (2006) 3053-3060
9. Bradshaw H.B., Rimmerman N., Krey J.F., and Walker J.M. Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291 (2006) R349-R358
10. Cani P.D., Montoya M.L., Neyrinck A.M., Delzenne N.M., and Lambert D.M. Potential modulation of plasma ghrelin and glucagon-like peptide-1 compounds, SR141716A (rimonabant) and oleoylethanolamide. Br. J. Nutr. 92 (2004) 757-761
11. Carpentier Y.A., Portois L., and Malaisse W.J. n-3 Fatty acids and the metabolic syndrome. Am. J. Clin. Nutr. 83 6 Suppl. (2006) 1499S-1504S (review)
12. Cavuoto P., McAinch A.J., Hatzinikolas G., Janovská A., Game P., and Wittert G.A. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem. Biophys. Res. Commun. 364 (2007) 105-110
13. Cota D., Marsicano G., Tschöp M., Grübler Y., Flachskamm C., Schubert M., Auer D., Yassouridis A., Thöne-Reineke C., Ortmann S., Tomassoni F., Cervino C., Nisoli E., Linthorst A.C., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112 (2003) 423-431
14. Cota D., Steiner M.A., Marsicano G., Cervino C., Herman J.P., Grübler Y., Stalla J., Pasquali R., Lutz B., Stalla G.K., and Pagotto U. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 148 (2007) 1574-1581
15. Cote M., Matias I., Lemieux I., Petrosino S., Almeras N., Despres J.P., and Di Marzo V. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int. J. Obes. 31 (2007) 692-699
16. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., and Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (1996) 83-87
17. Darmani N.A., Izzo A.A., Degenhardt B., Valenti M., Scaglione G., Capasso R., Sorrentini I., and Di Marzo V. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48 (2005) 1154-1163
18. de Miguel R., Romero J., Muñoz R.M., García-Gil L., González S., Villanua M.A., Makriyannis A., Ramos J.A., and Fernández-Ruiz J.J. Effects of cannabinoids on prolactin and gonadotrophin secretion: involvement of changes in hypothalamic gamma-aminobutyric acid (GABA) inputs. Biochem. Pharmacol. 56 10 (1998) 1331-1338 Nov 15
19. Després J.P., Golay A., Sjostrom L., and Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353 (2005) 2121-2134
20. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34 (1988) 605-613
21. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
22. Di Marzo V., Goparaju S.K., Wang L., Liu J., Bátkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., and Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-855
23. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8 (2005) 585-589
24. Di Marzo, V., Capasso, R., Matias, I., Aviello, G., Petrosino, S., Borrelli, F., Romano, B., Orlando, P., Capasso, F., Izzo, A.A., in press. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high fat diet. Br. J. Pharmacol.
25. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., and Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10819-10824
26. Engeli S., Bohnke J., Feldpausch M., Gorzelniak K., Janke J., Bátkai S., Pacher P., Harvey-White J., Luft F.C., Sharma A.M., and Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (2005) 2838-2843
27. Gammon C.M., Freeman Jr. G.M., Xie W., Petersen S.L., and Wetsel W.C. Regulation of gonadotropin-releasing hormone secretion by cannabinoids. Endocrinology 146 10 (2005) 4491-4499
28. Gasperi V., Fezza F., Pasquariello N., Bari M., Oddi S., Agro A.F., and Maccarrone M. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol. Life Sci. 64 (2007) 219-229
29. González S., Bisogno T., Wenger T., Manzanares J., Milone A., Berrendero F., Di Marzo V., Ramos J.A., and Fernández-Ruiz J.J. Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem. Biophys. Res. Commun. 270 (2000) 260-266
30. Habayeb O.M., Taylor A.H., Evans M.D., Cooke M.S., Taylor D.J., Bell S.C., and Konje J.C. Plasma levels of the endocannabinoid anandamide in women-a potential role in pregnancy maintenance and labor?. J. Clin. Endocrinol. Metab. 89 (2004) 5482-5487
31. Janiak P., Poirier B., Bidouard J.P., Cadrouvele C., Pierre F., Gouraud L., Barbosa I., Dedio J., Maffrand J.P., Le Fur G., O'Connor S., and Herbert J.M. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats. Kidney Int. 72 (2007) 1345-1357
32. Jbilo O., Ravinet-Trillou C., Arnone M., Buisson I., Bribes E., Péleraux A., Pénarier G., Soubrie P., Le Fur G., Galiègue S., and Casellas P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19 (2005) 1567-1569
33. Jensen D.P., Andreasen C.H., Andersen M.K., Hansen L., Eiberg H., Borch-Johnsen K., Jorgensen T., Hansen T., and Pedersen O. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. J. Mol. Med. 85 (2007) 445-449
34. Joyeux M., Arnaud C., Godin-Ribuot D., Demenge P., Lamontagne D., and Ribuot C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc. Res. 55 (2002) 619-625
35. Juan-Pico P., Fuentes E., Bermudez-Silva F.J., Javier Diaz-Molina F., Ripoll C., Rodriguez de Fonseca F., and Nadal A. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium 39 (2006) 155-162
36. Kankaanpää M., Lehto H.R., Pärkkä J.P., Komu M., Viljanen A., Ferrannini E., Knuuti J., Nuutila P., Parkkola R., and Iozzo P. Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J. Clin. Endocrinol. Metab. 91 (2006) 4689-4695
37. Kola B., Hubina E., Tucci S.A., Kirkham T.C., Garcia E.A., Mitchell S.E., Williams L.M., Hawley S.A., Hardie D.G., Grossman A.B., and Korbonits M. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J. Biol. Chem. 280 (2005) 25196-25201
38. Koura Y., Ichihara A., Tada Y., Kaneshiro Y., Okada H., Temm C.J., Hayashi M., and Saruta T. Anandamide decreases glomerular filtration rate through predominant vasodilation of efferent arterioles in rat kidneys. J. Am. Soc. Nephrol. 15 (2004) 1488-1494
39. Lazzarin N., Valensise H., Bari M., Ubaldi F., Battista N., Finazzi-Agrò A., and Maccarrone M. Fluctuations of fatty acid amide hydrolase and anandamide levels during the human ovulatory cycle. Gynecol. Endocrinol. 18 (2004) 212-218
40. Li J., and Wang D.H. Differential mechanisms mediating depressor and diuretic effects of anandamide. J. Hypertens. 24 (2006) 2271-2276
41. Liu Y.L., Connoley I.P., Wilson C.A., and Stock M.J. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int. J. Obes. (Lond.) 29 (2005) 183-187
42. Maccarrone M., Fride E., Bisogno T., Bari M., Cascio M.G., Battista N., Finazzi-Agrò A., Suris R., Mechoulam R., and Di Marzo V. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Mol. Hum. Reprod. 11 (2005) 21-28
43. Malcher-Lopes R., Di S., Marcheselli V.S., Weng F.J., Stuart C.T., Bazan N.G., and Tasker J.G. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J. Neurosci. 26 (2006) 6643-6650
44. Matias I., Carta G., Murru E., Petrosino S., Banni S., and Di Marzo V. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim. Biophys. Acta 1781 (2008) 52-60
45. Matias I., and Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol. Metab. 18 (2007) 27-37
46. Matias I., Gonthier M.P., Orlando P., Martiadis V., De Pertocellis L., Cervino C., Petrosino S., Hoareau L., Festy F., Pasquali R., Roche R., Maj M., Pagotto U., Monteleone P., and Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91 (2006) 3171-3180
47. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almong S., Martin B.R., Compton D.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50 (1995) 83-90
48. Montani J.P., Carroll J.F., Dwyer T.M., Antic V., Yang Z., and Dulloo A.G. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int. J. Obes. Relat. Metab. Disord. 28S4 (2004) S58-S65
49. Monteleone P., Matias I., Martiadis V., De Petrocellis L., Maj M., and Di Marzo V. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 30 (2005) 1216-1221
50. Mukhopadhyay P., Bátkai S., Rajesh M., Czifra N., Harvey-White J., Haskó G., Zsengeller Z., Gerard N.P., Liaudet L., Kunos G., and Pacher P. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll. Cardiol. 50 (2007) 528-536
51. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
52. Nakata M., and Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca(2+) oscillation in islet beta-cells via CB1 receptors. Regul. Pept. 145 (2008) 49-53
53. Niederhoffer N., Hansen H.H., Fernandez-Ruiz J.J., and Szabo B. Effects of cannabinoids on adrenaline release from adrenal medullary cells. Br. J. Pharmacol. 134 6 (2001) 1319-1327
54. Nobukata H., Ishikawa T., Obata M., and Shibutani Y. Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats. Metabolism 49 (2000) 912-919
55. Okamoto Y., Morishita J., Tsuboi K., Tonai T., and Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279 (2004) 5298-5305
56. Osei-Hyiaman D., DePetrillo M., Pacher P., Liu J., Radaeva S., Bátkai S., Harvey-White J., Mackie K., Offertaler L., Wang L., and Kunos G. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115 (2005) 1298-1305
57. Pacher P., Bátkai S., and Kunos G. Cardiovascular pharmacology of cannabinoids. Handb. Exp. Pharmacol. 168 (2005) 599-625
58. Pagano C., Pilon C., Calcagno A., Urbanet R., Rossato M., Milan G., Bianchi K., Rizzuto R., Bernante P., Federspil G., and Vettor R. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via PI3-kinase and calcium-dependent mechanisms. J. Clin. Endocrinol. Metab. 92 (2007) 4810-4819
59. Pagotto U., Marsicano G., Cota D., Lutz B., and Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr. Rev. 27 (2006) 73-100
60. Petersen G., Sorensen C., Schmid P.C., Artmann A., Tang-Christensen M., Hansen S.H., Larsen P.J., Schmid H.H., and Hansen H.S. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim. Biophys. Acta 1761 (2006) 143-150
61. Porcella A., Marchese G., Casu M.A., Rocchitta A., Lai M.L., Gessa G.L., and Pani L. Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. Eur. J. Endocrinol. 147 (2002) 255-261
62. Rajesh M., Mukhopadhyay P., Bátkai S., Haskó G., Liaudet L., Huffman J.W., Csiszar A., Ungvari Z., Mackie K., Chatterjee S., and Pacher P. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol. 293 (2007) H2210-H2218
63. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J.P., and Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284 (2003) R345-R353
64. Roche R., Hoareau L., Bes-Houtmann S., Gonthier M.P., La Borde C., Baron J.F., Hafaf Y., Cesari M., and Festy F. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem. Cell. Biol. 126 (2006) 177-187
65. Rossi G., Gasperi V., Paro R., Barsacchi D., Lecconi S., and Maccarrone M. Follicle-stimulating hormone activates fatty acid amide hydrolase by protein kinase A and aromatase-dependent pathways in mouse primary Sertoli cells. Endocrinology 148 (2007) 1431-1439
66. Scheen A.J., Finer N., Hollander P., Jensen M.D., Van Gaal L.F., and RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006) 1660-1672
67. Scorticati C., Fernández-Solari J., De Laurentiis A., Mohn C., Prestifilippo J.P., Lasaga M., Seilicovich A., Billi S., Franchi A., McCann S.M., and Rettori V. The inhibitory effect of anandamide on luteinizing hormone-releasing hormone secretion is reversed by estrogen. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11891-11896
68. Sipe J.C., Waalen J., Gerber A., and Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int. J. Obes. 29 (2005) 755-759
69. Shmist Y.A., Goncharov I., Eichler M., Shneyvays V., Isaac A., Vogel Z., and Shainberg A. Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol. Cell. Biochem. 283 (2006) 75-83
70. Spoto B., Fezza F., Parlongo G., Battista N., Sgro' E., Gasperi V., Zoccali C., and Maccarrone M. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 88 (2006) 1889-1897
71. Starowicz, K., Cristino, L., Matias, I., Capasso, R., Racioppi, A., Cascio M.G., Izzo, A.A., Di Marzo, V. in press. Effect of a high fat diet on endocannabinoid receptor and metabolic enzyme expression in mouse pancreas and adipose tissue. Obes. Res.
72. Steffens S., and Mach F. Toward a therapeutic use of cannabinoid CB(2) receptor in atherosclerosis. Med. Sci. (Paris) 22 (2006) 7-9
73. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., and Waku K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215 (1995) 89-97
74. Tucci S.A., Rogers E.K., Korbonits M., and Kirkham T.C. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br. J. Pharmacol. 143 (2004) 520-523
75. Wagner J.A., Abesser M., Harvey-White J., and Ertl G. 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J. Cardiovasc. Pharmacol. 47 (2006) 650-655
76. Wagner J.A., Abesser M., Karcher J., Laser M., and Kunos G. Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. J. Cardiovasc. Pharmacol. 46 (2005) 348-355
77. Wang H., Dey S.K., and Maccarrone M. Jekyll and hyde: two faces of cannabinoid signaling in male and female fertility. Endocr. Rev. 27 (2006) 427-448
78. Wang L., and Wang D.H. TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in mice. Circulation. 112 (2005) 3617-3623
79. Watanabe S., Doshi M., and Hamazaki T. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot. Essent. Fatty Acids 69 (2003) 51-59
80. Wenger T., Ledent C., Csernus V., and Gerendai I. The central cannabinoid receptor inactivation suppresses endocrine reproductive functions. Biochem. Biophys. Res. Commun. 284 June 8 (2) (2001) 363-368
81. Yan Z.C., Liu D.Y., Zhang L.L., Shen C.Y., Ma Q.L., Cao T.B., Wang L.J., Nie H., Zidek W., Tepel M., and Zhu Z.M. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem. Biophys. Res. Commun. 354 (2007) 427-433
82. Zhong B., and Wang D.H. TRPV1 gene knockout impairs preconditioning protection against myocardial injury in isolated perfused hearts in mice. Am. J. Physiol. Heart. Circ. Physiol. 293 (2007) H1791-H1798
83. Zhu Y., Xie C., and Wang D.H. TRPV1-mediated diuresis and natriuresis induced by hypertonic saline perfusion of the renal pelvis. Am. J. Nephrol. 27 (2007) 530-537
84. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sørgård M., Di Marzo V., Julius D., and Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457